Skip to Content

Viekira Pak Approval History

  • FDA approved: Yes (First approved December 19th, 2014)
  • Brand name: Viekira Pak
  • Generic name: ombitasvir/paritaprevir/ritonavir with dasabuvir
  • Dosage form: Tablets
  • Company: AbbVie Inc.
  • Treatment for: Hepatitis C

Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) is an NS5A inhibitor, NS3/4A protease inhibitor and CYP3A inhibitor combination co-packaged with a non-nucleoside NS5B palm polymerase inhibitor for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.

Development History and FDA Approval Process for Viekira Pak

Dec 19, 2014Approval FDA Approves Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) to Treat Hepatitis C
Apr 22, 2014AbbVie Submits NDA to FDA for Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.